Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Next Previous
Trial Profile

A Prospective Open-label Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RT 001 (Primary)
  • Indications Neuroaxonal dystrophies
  • Focus Registrational; Therapeutic Use
  • Sponsors Retrotope

Most Recent Events

  • 26 Apr 2022 Primary endpoint Modified Ashworth Spasticity Scale has not been met, according to Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
  • 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 06 Oct 2021 According to a Retrotope media release, Darius J. Adams and Alex Fay are the principal investigator of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top